State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Xi Road, Guangzhou, Guangdong, 510120, China.
Shunde Hospital Affiliated to Guangzhou University of Chinese Medicine, FoShan, 528000, China.
BMC Infect Dis. 2024 Jan 16;24(1):92. doi: 10.1186/s12879-024-09014-8.
BACKGROUND/OBJECTIVE: With the development of society, pulmonary fungal diseases, represented by pulmonary aspergillosis and pulmonary cryptococcosis, have become increasingly common. However, there is a lack of clear understanding regarding coinfection by these two types of fungi in immunocompetent individuals.
A retrospective study from 2014 to 2022 and a systematic literature review of original articles published in English were performed. Patients with pulmonary cryptococcosis complicated with pulmonary aspergillosis including 5 in the retrospective study and 6 in the systematic literature review.
The diagnosis of concurrent pulmonary cryptococcosis and pulmonary aspergillosis in patients was confirmed through repeated biopsies or surgical resection. Pulmonary cryptococcosis is often diagnosed initially (6/11, 55%), while the diagnosis of pulmonary aspergillosis is established when the lesions become fixed or enlarged during treatment. Transbronchial lung biopsy (3/11, 27%), thoracoscopic lung biopsy (2/11, 18%), and percutaneous aspiration biopsy of the lung (1/11, 9%) were the main methods to confirm concurrent infection. Most patients were treated with voriconazole, resulting in a cure for the coinfection (6/11, 55%).
Pulmonary cryptococcosis complicated with pulmonary Aspergillus is an easily neglected mixed fungal infection. During the treatment of lesion enlargement in clinical cryptococcus, we need to watch out for Aspergillus infection.
背景/目的:随着社会的发展,以肺曲霉病和肺隐球菌病为代表的肺部真菌感染越来越常见。然而,对于免疫功能正常者同时感染这两种真菌的情况,人们缺乏明确的认识。
对 2014 年至 2022 年的回顾性研究和英文原始文献的系统综述进行了回顾。包括回顾性研究中的 5 例和系统综述中的 6 例合并肺隐球菌病和肺曲霉病的患者。
通过反复活检或手术切除,确认了患者合并肺隐球菌病和肺曲霉病的诊断。肺隐球菌病通常是最初诊断(6/11,55%),而当病变在治疗过程中变得固定或增大时,才确定肺曲霉病的诊断。经支气管肺活检(3/11,27%)、胸腔镜肺活检(2/11,18%)和经皮肺穿刺活检(1/11,9%)是确认合并感染的主要方法。大多数患者接受伏立康唑治疗,合并感染得到治愈(6/11,55%)。
肺隐球菌病合并肺曲霉病是一种容易被忽视的混合真菌感染。在临床隐球菌病治疗中病变增大时,我们需要警惕曲霉感染。